Eli Lilly Just Spent $25 Billion in Six Months — and It’s Still Shopping

Eli Lilly has committed more than $25 billion to acquisitions in the first half of 2026 — more money than the rest of Big Pharma’s top players combined spent on deals in the same period. And the trillion-dollar drugmaker shows no sign of slowing down.

A Deal Pace Pharma Has Never Seen

The Indianapolis-based company has signed roughly 10 acquisitions since January, seven of them in a single three-month stretch. The targets stretch far beyond the obesity drugs that made Lilly famous: sleep medicine, blood cancers, cell therapy, vaccines, and even DNA editing.

The biggest checks so far: up to $7.8 billion for sleep-drug developer Centessa Pharmaceuticals and up to $7 billion for cancer cell-therapy company Kelonia Therapeutics — two of the largest deals in Lilly’s history.

The Reason Behind the Rush

Here’s the part most headlines skip. Lilly’s two blockbuster drugs — Mounjaro for diabetes and Zepbound for obesity — now generate more than 60% of the company’s total revenue. Zepbound alone controls roughly 70% of the branded obesity market.

That kind of dominance is a strength today and a risk tomorrow. Patents expire. Competitors catch up. Pricing rules change. Lilly is using its record profits to buy its next decade of growth before the GLP-1 gold rush cools.

The Numbers Driving It

• $1.06 trillion — Lilly’s market cap, the first drugmaker ever to cross that line
• 56.9% — stock gain over the past year, from about $774 to $1,214 per share
• $82–$85 billion — the company’s own revenue forecast for 2026
• 10 deals, ~$25.27 billion — Lilly’s 2026 shopping tally so far

What It Means

Eli Lilly isn’t just riding the obesity wave anymore — it’s converting that windfall into an entirely new company spanning cancer, sleep, Alzheimer’s, and vaccines. For the rest of the pharmaceutical industry, the message is uncomfortable: the biggest player is also the fastest-moving one.

For the full story behind Lilly’s acquisition machine — every deal, the strategy, and what comes next — read our complete analysis: https://truepickus.com/eli-lilly-acquisitions-strategy.

— William Harris, TruePickUS | July 10, 2026